Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 12:11 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 901 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo Once Weekly Clear all

Conditions: Eosinophilic Esophagitis
Interventions: RPC4046, Placebo; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 27
States / cities: Scottsdale, Arizona • Tucson, Arizona • Oceanside, California + 24 more

Conditions: Nonalcoholic Steatohepatitis
Interventions: Tirzepatide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 47
States / cities: Birmingham, Alabama • Chandler, Arizona • Fresno, California + 37 more

Conditions: Atopic Dermatitis, Eczema
Interventions: Bermekimab Monoclonal Antibody, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 17
States / cities: Huntington Beach, California • Coral Gables, Florida • Doral, Florida + 11 more

Conditions: Hepatitis C Virus
Interventions: BMS-791325, Placebo, Peg-interferon alfa-2a, Ribavirin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 10
States / cities: Anaheim, California • Maywood, Illinois • Baltimore, Maryland + 6 more

Conditions: Demoralization
Interventions: Psilocybin, Placebo; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 25 Years to 65 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: End Stage Renal Disease, Kidney Disease, Protein Energy Wasting
Interventions: PINTA 745, Placebo; Drug
Lead sponsor: Pinta Biotherapeutics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 6
States / cities: Lakewood, Colorado • Orlando, Florida • Minneapolis, Minnesota + 3 more

Conditions: End-stage Renal Disease
Interventions: Vitamin D3, Placebo; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Hypertension, Obesity
Interventions: CagriSema, Semaglutide, Cagrilintide, Placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 1,408 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 57
States / cities: Concord, California • Costa Mesa, California • Fullerton, California + 47 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Semaglutide, Placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 245 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 101
States / cities: Birmingham, Alabama • Banning, California • Chula Vista, California + 83 more

Conditions: Chronic Plaque Psoriasis
Interventions: Secukinumab 300 mg, Placebo; Drug · Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 12
States / cities: Los Angeles, California • Santa Ana, California • Rockville, Maryland + 8 more

Conditions: Type 2 Diabetes, End Stage Renal Disease on Dialysis
Interventions: Semaglutide, Placebo; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 5
States / cities: Chapel Hill, North Carolina • Dallas, Texas • Irving, Texas

Conditions: Arthritis, Rheumatoid
Interventions: GSK3196165 (Otilimab), Tofacitinib, Placebo; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 1,764 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 64
States / cities: Flagstaff, Arizona • Glendale, Arizona • Mesa, Arizona + 58 more

Conditions: Rheumatoid Arthritis
Interventions: Atacicept, Placebo matched to atacicept; Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years and older
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Rockland, Massachusetts

Conditions: Hereditary Angioedema
Interventions: Recombinant human C1 inhibitor, Placebo; Biological · Other
Lead sponsor: Pharming Technologies B.V.; Industry
Eligibility: 13 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 4
States / cities: Tampa, Florida • St Louis, Missouri • Lake Oswego, Oregon

Conditions: Recurrent Genital Herpes Simplex Type 2
Interventions: ABI-1179, ABI-1179 Placebo; Drug
Lead sponsor: Assembly Biosciences; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 103 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 4
States / cities: Kansas City, Missouri • Rochester, New York • Seattle, Washington

Conditions: Relapsing Multiple Sclerosis
Interventions: Ozanimod, Placebo; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 6
States / cities: Berkeley, California • Fresno, California • Sacramento, California + 3 more

Conditions: Tobacco Use
Interventions: Semaglutide, Placebo; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Obesity or Overweight
Interventions: AZD6234, Placebo comparator; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 262 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 23
States / cities: Mobile, Alabama • Phoenix, Arizona • Long Beach, California + 19 more

Conditions: Triple Negative Breast Cancer
Interventions: Placebo, Atezolizumab; Drug
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years and older
Enrollment: 1,550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 212
States / cities: Mobile, Alabama • Anchorage, Alaska • Jonesboro, Arkansas + 164 more

Conditions: Diabetes Mellitus
Interventions: Exenatide, Exenatide matching placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 464 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 68
States / cities: Birmingham, Alabama • Huntsville, Alabama • Muscle Shoals, Alabama + 56 more

Conditions: Type 2 Diabetes Mellitus
Interventions: exenatide once weekly, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 19 Years to 75 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Smoking Cessation
Interventions: Exenatide, NRT, Counseling, Placebo; Drug · Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 75 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Attention Deficit/Hyperactivity Disorder
Interventions: Ritalin LA (methylphenidate hydrochloride extended release); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 299 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 16
States / cities: Little Rock, Arkansas • Beverly Hills, California • Spring Valley, California + 12 more

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: liraglutide, sitagliptin, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 407 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 58
States / cities: Phoenix, Arizona • Tucson, Arizona • Escondido, California + 46 more

Search by objective public record fields.

Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis

A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)

A Study to Evaluate the Safety and Efficacy of Bermekimab in Patients With Moderate to Severe Atopic Dermatitis

Ph IIA Study (SOC +/- NS5B)

Exploratory Study of Low Dose Psilocybin

Effects of PINTA 745 in End Stage Renal Disease (ESRD) Patients Who Require Hemodialysis and Have Protein Energy Wasting

Vitamin D and Arteriovenous Fistulae

A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and Obesity

A Research Study to Look Into How Well Semaglutide Medicine Works at Different Doses in People With Type 2 Diabetes and Overweight

Study to Evaluate the Effect of Secukinumab Compared to Placebo on Aortic Vascular Inflammation in Subjects With Moderate to Severe Plaque Psoriasis

DIALYSIS-TIR Study

Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs)

A Phase 2 Dose-finding Study of Atacicept in Subjects With Rheumatoid Arthritis (AUGUST I)

A Phase 2 HAE Prophylaxis Study With Recombinant Human C1 Inhibitor

A Study to Assess the Safety, Pharmacokinetics, and Tolerability of ABI-1179 in Healthy Subjects and in Subjects Seropositive for HSV-2 With Recurrent Genital Herpes

Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients

Impact of Semaglutide on Tobacco Use and Related Health Behaviors

A Study in Participants With Obesity or Overweight With at Least One Weight-related Comorbidity

Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo

Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus

A Study to Examine the Pharmacokinetics, Tolerability, Safety and Efficacy of Exenatide Once Weekly Suspension

Exenatide Once Weekly for Smoking Cessation

Open-label Extension Evaluating Methylphenidate Hydrochloride Extended Release in Adults With Attention Deficit/Hyperactivity Disorder

Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin